Morten Nissen - Scandion Oncology G Counsel
| SCOL Stock | SEK 0.06 0.01 9.70% |
Insider
Morten Nissen is G Counsel of Scandion Oncology AS
| Phone | 45 38 10 20 17 |
| Web | https://www.scandiononcology.com |
Scandion Oncology Management Efficiency
The company has return on total asset (ROA) of (0.4236) % which means that it has lost $0.4236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.7402) %, meaning that it generated substantial loss on money invested by shareholders. Scandion Oncology's management efficiency ratios could be used to measure how well Scandion Oncology manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Bent MSc | ExpreS2ion Biotech Holding | N/A | |
| Jorgen Drejer | Saniona AB | 68 | |
| Keith Alexander | ExpreS2ion Biotech Holding | N/A | |
| Pr MD | Oncopeptides AB | N/A | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Annika MBA | Oncopeptides AB | 57 | |
| Henrik Hang | Fluoguide AS | 41 | |
| BBA MD | Fluoguide AS | 58 | |
| Klaus Sindahl | Hansa Biopharma AB | N/A | |
| Mette Thorn | ExpreS2ion Biotech Holding | N/A | |
| Katja Margell | Hansa Biopharma AB | N/A | |
| Linda Holmstrom | Oncopeptides AB | N/A | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Lars Petersen | ExpreS2ion Biotech Holding | N/A | |
| Anita BCom | Saniona AB | 55 | |
| Palle MS | Saniona AB | 65 | |
| Karin Nielsen | Saniona AB | N/A | |
| MSc MD | Oncopeptides AB | N/A | |
| Anne Lanner | Hansa Biopharma AB | 54 | |
| Mattis Ranthe | ExpreS2ion Biotech Holding | N/A | |
| Max Sogaard | ExpreS2ion Biotech Holding | N/A | |
Management Performance
| Return On Equity | -0.74 | |||
| Return On Asset | -0.42 |
Scandion Oncology Leadership Team
Elected by the shareholders, the Scandion Oncology's board of directors comprises two types of representatives: Scandion Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scandion. The board's role is to monitor Scandion Oncology's management team and ensure that shareholders' interests are well served. Scandion Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scandion Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Annie Rasmussen, Chief Director | ||
| Morten Nissen, G Counsel | ||
| Mads Kronborg, Head Communication | ||
| Nils MD, Scientific CoFounder | ||
| Johnny MS, CFO CEO | ||
| Alfredo MD, Chief Officer |
Scandion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Scandion Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.74 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | 473.28 % | |||
| Current Valuation | (6.85 M) | |||
| Shares Outstanding | 40.71 M | |||
| Shares Owned By Insiders | 1.82 % | |||
| Price To Book | 1.01 X | |||
| Price To Sales | 969.63 X | |||
| Gross Profit | (32.32 M) | |||
| EBITDA | (55.84 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Scandion Stock Analysis
When running Scandion Oncology's price analysis, check to measure Scandion Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandion Oncology is operating at the current time. Most of Scandion Oncology's value examination focuses on studying past and present price action to predict the probability of Scandion Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandion Oncology's price. Additionally, you may evaluate how the addition of Scandion Oncology to your portfolios can decrease your overall portfolio volatility.